Treatment of acute pulmonary embolism using rheolytic thrombectomy

Background: The AngioJet rheolytic thrombectomy (ART) system can quickly fragment and aspirate thrombi according to Bernoulli's principle. Aims: This retrospective study aimed to evaluate the therapeutic effects of the ART system in treating severe acute pulmonary embolism (APE), including high-risk pulmonary embolism (HR-PE) and intermediate-high-risk pulmonary embolism (IHR-PE). Methods: Forty-four APE patients (21 HR-PE and 23 IHR-PE) were enrolled and underwent pulmonary ART using the 6 Fr Solent Omni AngioJet device. Nineteen patients were diagnosed with APE and lower extremity deep venous thrombosis (LEDVT), and underwent thrombectomy of APE and LEDVT simultaneously using ART. All patients also received local thrombolysis with urokinase. Results: The results showed that the mean length of stay in intensive care units was 2.4 +/- 1.9 days. Significant improvements in clinical, haemodynamic and angiographic parameters were observed in both groups; the improvements in shock index, PaO2, and angiographic parameters were more obvious in the IHR-PE group. Six of the 44 patients died in hospital. During the follow-up, 35 of 38 patients were functioning well and no recurrence of APE was observed. Conclusions: Pulmonary ART plus local thrombolysis of the pulmonary artery for HR-PE or IHR-PE is feasible and appears to be safe. Further studies are warranted to investigate comparative efficacy compared to existing treatments.

Automated summary

This retrospective study evaluated the therapeutic effects of the AngioJet system in treating severe acute pulmonary embolism, demonstrating its safety and effectiveness when combined with local thrombolysis for HR-PE and IHR-PE. Significant improvements in clinical, haemodynamic, and angiographic parameters were observed post-procedure. Further studies are needed to compare efficacy with existing treatments.